TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease

Aislinn D. Maguire¹, John R. Bethea² and Bradley J. Kerr¹,³,⁴*

¹ Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada, ² Drexel University, Philadelphia, PA, United States, ³ Department of Pharmacology, University of Alberta, Edmonton, AB, Canada, ⁴ Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, AB, Canada

Multiple Sclerosis (MS) is a debilitating autoimmune disease often accompanied by severe chronic pain. The most common type of pain in MS, called neuropathic pain, arises from disease processes affecting the peripheral and central nervous systems. It is incredibly difficult to study these processes in patients, so animal models such as experimental autoimmune encephalomyelitis (EAE) mice are used to dissect the complex mechanisms of neuropathic pain in MS. The pleiotropic cytokine tumor necrosis factor α (TNFα) is a critical factor mediating neuropathic pain identified by these animal studies. The TNF signaling pathway is complex, and can lead to cell death, inflammation, or survival. In complex diseases such as MS, signaling through the TNFR1 receptor tends to be pro-inflammatory and death, whereas signaling through the TNFR2 receptor is pro-homeostatic. However, most TNFα-targeted therapies indiscriminately block both arms of the pathway, and thus are not therapeutic in MS. This review explores pain in MS, inflammatory TNF signaling, the link between the two, and how it could be exploited to develop more effective TNFα-targeting pain therapies.

Keywords: pain, cytokine, TNF-α, EAE (experimental autoimmune encephalomyelitis), NFκapapB, MAP kinase (MAPK), autoimmune disease

MS AND ITS MOUSE MODELS

MS Background

Multiple Sclerosis (MS) is an autoimmune disease characterized by aberrant immune cell activity leading to inflammation and demyelinating lesions of central nervous system (CNS) (1–3). It’s causes, while not fully understood, are likely a combination of genetic and environmental factors (4). The MS disease course can follow multiple trajectories. Primary progressive disease worsens steadily from onset. Progressive relapsing disease increasingly worsens but with some relapsing characteristics, meaning there are periods where symptoms worsen, then improve again. Most patients have a biphasic disease course, wherein they initially present with a relapsing-remitting phenotype, but as the disease progresses there is a switch to the secondary progressive phenotype and disability continually worsens (2, 5). There are numerous symptoms and comorbidities associated with MS, which can affect sensory, motor, and cognitive modalities. One of the most debilitating ailments experienced by MS patients is chronic pain (6, 7).

Pain in MS

Pain is a common feature for many patients diagnosed with MS (6, 8). The pain MS patients may encounter includes chronic headache, sudden neck pain called Lhermitte’s sign, trigeminal
neuralgia, extremity pain and hypersensitivity due to neuropathy (central or peripheral) (9). Pain is one of the most devastating comorbidities of MS, significantly interfering with daily life and yet, there are few treatments available (9–11). This is likely because neuropathic pain (NP), chronic pain that is caused by injury or disease of the nervous system, underlies most pain in MS (12). Neuropathic pain cannot be treated with typical painkillers such as opioids or anti-inflammatory drugs but instead, is often treated with more non-specific drugs like anti-depressants or anti-convulsants which have severe side effects (9, 11, 13, 14). Treating neuropathic pain in autoimmune diseases is further complicated by a process called sensitization, which occurs in both the peripheral and central nervous system (PNS and CNS). Sensitization can involve both intra and intercellular changes that increase pain sensations and allow for the maintenance of pain regardless of disease progression or treatment (15). Studies in similar autoimmune diseases (namely Rheumatoid Arthritis) have demonstrated that pain is often not resolved by disease-modifying treatment, and must be studied and treated separately (16). To study the mechanisms of pain in MS, researchers have turned to animal models which exhibit comparable disease phenotypes in the PNS and CNS, and most importantly, pain.

Mouse Models of MS

There are several paradigms used to induce MS-like symptoms in laboratory animals. Although MS models have been developed in rats, non-human primates, and even zebrafish, the greatest diversity exists in mouse models (17). MS models are categorized into three main groups, though viral infection, self-antigens that become recognized by the immune system, or toxins that cause demyelination. Theiler’s murine encephalomyelitis virus (TMEV) induced disease is the best example of a viral induced model of MS, while experimental autoimmune encephalomyelitis (EAE) represents the prototypical antigen induced disease model, and demyelination is induced by cuprizone or lysophosphatidyl choline (LPC) administration (Table 1).

Due to its induction method, mice infected with TMEV develop a biphasic disease phenotype that is useful for studying the viral contribution to MS (18, 19). EAE on the other hand, refers to a variety of ways to induce immune activation and demyelination that mimic MS pathophysiology. This is most often achieved by immunization with a myelin antigen. For example, EAE induced in Swiss Jim Lambert (SJL) mice with a fragment of proteolipid protein (PLP139–151) causes a relapsing-remitting disease phenotype (21). A primary progressive phenotype can be induced by immunization with myelin oligodendrocyte glycoprotein (MOG35–55) emulsified in an adjuvant such as CFA to trigger an immune response to myelin (27, 28, 39, 40). By modifying the concentration of MOG35–55 and the adjuvants used to induce EAE, a relapsing-remitting phenotype in C57Bl/6 mice can also be generated (29, 30, 41). MOG EAE immunization protocols are normally followed by injections with pertussis toxin to facilitate blood brain barrier breakdown (39), but this step can also be omitted (34). QuilA can also be used in place of Complete Freund’s Adjuvant (CFA), the most used adjuvant in EAE models, to generate a relapsing-remitting phenotype (31).

Transgenic EAE is yet another method of mimicking MS in mice. T and/or B cells in these mice are genetically manipulated to react to MOG, and different strains have been developed to produce either a primary progressive or relapsing-remitting phenotype (23–26). Lastly, demyelination can be caused by either consumption of the copper chelator cuprizone which preferentially causes oligodendrocyte cell death (42, 43), or injection of LPC which integrates into membranes and disrupts myelin (44, 45). These models are useful to study demyelination separately from other MS disease processes. Although there are many ways to induce MS-like symptoms in mice, and each have their own strengths and weaknesses in modeling CNS lesions, demyelination, axonal damage, immune cell activation, they all produce pain (20, 22, 35).

Pain in MS Models

Animal models of MS have enabled researchers to study the mechanisms of chronic pain associated with the disease as the animals develop similar pain phenotypes to people with MS (46). Like MS patients, mice with EAE also exhibit cold and mechanical hypersensitivity, trigeminal neuralgia, and even sex differences in pain (9, 47, 48). Animals with TMEV and EAE exhibit hypersensitivity to painful and non-painful stimuli called, called hyperalgesia and allodynia, respectively (20, 46, 49). Interestingly, TMEV animals present with sex differences

| Name        | Induction method                          | Disease phenotype     | Does it cause Pain? | References |
|-------------|------------------------------------------|-----------------------|---------------------|------------|
| TMEV        | Viral infection                          | Biphasic              | Yes                 | (18–20)   |
| SJL/J EAE   | Immunization with PLP<sub>139–151</sub>   | Relapsing-remitting   | Yes                 | (21, 22)  |
| Transgenic EAE | Mice with genetically manipulated T and/or B cells | Primary progressive or relapsing-remitting | Yes | (23–26) |
| Pertussis/CFA EAE | Immunization with MOG emulsified in CFA, then pertussis | Primary progressive or relapsing-remitting | Yes | (27, 28) |
| Pertussis/QuilA EAE | Immunization with MOG emulsified in QuilA, then pertussis | Relapsing-remitting | Yes | (29–33) |
| Non-pertussis EAE | Immunization with MOG in CFA, no pertussis | Primary progressive | Yes | (34) |
| Cuprizone   | Administered in diet for 5+ weeks         | Demyelinating         | Yes                 | (35)       |
| LPC         | Peripheral or central injection           | Demyelinating         | Yes                 | (36–38)   |
in pain, with females developing hypersensitivity more quickly than males (20). This sex difference is important as it allows researchers to better understand sex differences in human MS. In a foundational study of pain in EAE, animals exhibited heat-induced hyperalgesia not only when the disease was induced by immunization with a myelin peptide emulsified in CFA, but also when T cells from EAE mice were transferred to naïve mice (50). The cuprizone model has historically been studied less in the context of pain, but a recent study using electrical stimulation-induced paw withdrawal suggests there is a pain phenotype in cuprizone mice (35). LPC injection has also been associated with pain, but more commonly in the context of nerve or spinal cord injury (36–38).

One mechanism that may be responsible for some aspects of pain in MS animal models is immune cell activation and cytokine release, generating peripheral and central sensitization. Tumor necrosis factor alpha (TNFα) is of the most prominent pro-inflammatory cytokines present in MS and EAE, and it also has strong associations with many other chronic pain conditions (51–53).

**TNFα STRUCTURE AND FUNCTION**

**TNFα Signaling**

TNFα is a pleiotropic cytokine with a multifaceted signaling pathway which can lead to cell death via either apoptosis or necrosis, or conversely, to survival and inflammation (Figure 1). TNFα originates in its transmembrane form (tmTNFα), produced by immune cells such as macrophages, monocytes, and lymphocytes (54, 55). Then it may be cleaved by TNFα converting enzyme (TACE) and released into its soluble form (sTNFα) (55). As the main determinant of TNFα isoform availability, TACE overactivity has been linked to inflammatory diseases (56). However, it is not currently a viable treatment target due to its similarity to other matrix metalloproteinases (57). There are two main subtypes of TNF receptors, TNFR1 and
TNFR2. TNFR1 is expressed on most cell types and primarily mediates pro-inflammatory and pro-death signaling (58). It can bind both sTNFα and tmTNFα, but is preferentially activated by sTNFα (59, 60). TNFα is expressed mostly on immune cells and only associates with tmTNFα (61, 62). This receptor lacks a death domain and is associated with pro-survival and pro-homeostatic signaling (62). Interestingly, during this interaction, tmTNFα also transmits signals back into its host cell (55).

sTNFα molecules act in a trimer and associate with three TNFR1 receptor subunits to activate the signaling complex by endocytosis into the cytoplasm (63). Next, Tumor necrosis factor receptor type 1-associated death domain protein (TRADD) associates with the receptor-ligand trimer. Further complex recruitment by TRADD then determines whether death or inflammation and survival will occur (63). Death signaling ensues if TRADD recruits fas-associated protein with death domain (FADD), and receptor-interacting serine/threonine-protein kinase (RIK) 1 (64). Cell death occurs by apoptosis if initiator caspases 8 or 10 are recruited, or by necroptosis if RIPK3 and mixed lineage kinase domain-like pseudokinase (MLKL) are recruited (64). The pro-survival factor, TNF receptor-associated factor 2 (TRAF2) can prevent cell death by acting as an E3 ubiquitin ligase to target RIPK1 for degradation (65, 66). TRAF2 then initiates activation of the mitogen-activated protein kinases (MAPKs) P38, c-Jun-N-terminal kinase (JNK), and extracellular signal-regulate kinase (ERK), or the transcription factor nuclear factor kappa B (NFκB) (65). Pro-inflammatory signaling by these factors is a beneficial response to insults such as infection, but it can also be maladaptive, leading to pain (67, 68).

TNFα also promotes activation of T cells (51). Non-specific TNFα antagonists have shown some effectiveness in relieving pain in RA, but not in all inflammatory pain conditions in which the cytokine might be involved, such as MS (99, 100).

### TNFα in MS and EAE

TNFα signaling may be involved in MS pathogenesis through several points of action. TNFα is elevated centrally in MS patients, and this is correlated with disease severity (101). However, it is incredibly difficult to study the precise mechanisms underlying TNFα signaling in MS in humans. Much of the proposed actions of TNFα in MS have been discovered through study of animal models such as EAE. In both MS and its animal counterparts, the major pathological landmarks are immune cell infiltration into the CNS, and the development of demyelinating lesions which eventually lead to neuronal death. In EAE, TNFα transport is upregulated at the blood-brain barrier (BBB), as is TNFα expression by mast cells, which are involved in BBB breakdown (102). TNFα also promotes activation of T cells (103, 104), and is upregulated in demyelinating lesions in EAE where it is hypothesized to promote neuronal excitotoxicity and oligodendrocyte death (103, 105). Therefore, TNFα appears to play a significant role in the pathogenesis of MS and EAE.
FIGURE 2 | TNFα is involved in pathological pain processing in MS. In normal physiological pain processing, pain signals are sent from the periphery to the DRG, which relays information to the spinal cord then brain (1A,B). In neuropathic pain in MS, inflammation activates immune cells which secrete the pro-inflammatory cytokine, TNFα both peripherally and centrally (2A). It can then act back on the cells which produced it creating a positive feedback loop. TNFα contributes to sensitization of peripheral nociceptors and spinal dorsal horn neurons through mechanisms such as altered excitatory and inhibitory receptor expression (2B,C). These conditions lead to long term central pain sensitization of the brain and spinal cord (2D). This figure was made using BioRender.

TARGETING TNFα AS AN ANALGESIC STRATEGY

Anti-TNF Therapies

There are five non-specific TNFα inhibitors currently in clinical use (Table 2). Infliximab, Adalimumab, Golimumab, and Certolizumab are antibodies that target TNFα, and Etanercept is a soluble recombinant TNF receptor (119, 120). All of these drugs work by binding to and sequestering both the soluble and transmembrane forms of TNFα so they cannot interact with
their receptors and initiate signaling cascades (55). Anti-TNF drugs can be beneficial in various types of arthritis, ankylosing spondilitis, plaque psoriasis, Crohn’s disease, and ulcerative colitis (121). However, there are severe side effects associated with TNF inhibition. TNFα is an important immune-mediator, and blocking its actions can be immunosuppressive, thereby increasing the risk of new infections as well as re-activation of dormant infections (122, 123). There is also evidence these drugs cause demyelination and liver damage (124, 125). The severe side effects of TNF inhibition may be due to blockade of the homeostatic functions TNFα, particularly through TNFR2 signaling. This indiscriminate blockade of TNFα may also help to explain why pain management is lacking with anti-TNF treatment (126–128).

Anti-TNF therapies have mixed effectiveness in treating pain depending on the condition for which they are used. In a rat chronic constriction injury model of PNI, TNF inhibition reduced mechanical and thermal pain (99, 145). Pain reduction by anti-TNF drugs in PNI has been suggested to occur through an alteration of TNF receptor expression in the spinal cord (146). Anti-TNF treatment with either etanercept or infliximab decreased the TNFR1/TNFR2 ratio, and this correlated with better recovery (145). This finding conforms with the view of TNF receptors which considers TNFR1 to be involved in pathology/damage, and TNFR2 to be involved in repair and homeostasis (147, 148). Although it is unclear how exactly these anti-TNF drugs modulate receptor expression, these findings provide a strong rationale to further investigate TNF receptor modulation in neuropathic pain treatment, and there are currently drugs in development for this purpose (Table 2).

In another peripherally-driven chronic pain disorder, diabetic peripheral neuropathy (DPN), TNF inhibition blocked mechanical but not thermal pain in a rat model (99, 149). Anti-TNF treatment in this model has also improved signs of nerve degeneration associated with advancing DPN, restoring conduction velocity, myelination, myelin basic protein expression, as well as lamellar and axonal organization (150). Based on the findings in these two models, TNF inhibition can affect sensory neuron inflammation and degeneration, as well as spinal TNF receptor expression. It will be important for future
Anti-TNF in MS: The Double-Edged Sword

Anti-TNF therapies are generally not only ineffective in treating MS, but they can also worsen disease severity. They are also known to increase the risk of developing MS in patients receiving anti-TNF treatment for other conditions (124, 151, 152). Studies using EAE have provided insight into why universal blockade of TNF signaling can be detrimental in the disease. Anti-TNF molecules sequester both soluble and transmembrane TNFα and block signaling through both TNFR1 and TNFR2 (55). In EAE, inhibition of soluble TNFα signaling through TNFR1 promotes remyelination and axon survival (96). However, transmembrane TNFα signaling through TNFR2 may be neuroprotective (153). TNFR2 signaling supports regulatory T cells (Tregs) (98, 154), and promotes remyelination through oligodendrocyte differentiation (106). Ultimately, while blocking all TNF signaling in MS and EAE can reduce its detrimental effects, it also reduces the beneficial aspects of TNFR2 signaling, leading to a net negative result for anti-TNF therapies in MS and EAE.

Drugs that are more specifically targeted to cell type, TNFα isoform, and TNF receptor type will be necessary to further explore TNF therapies for disease modification and pain treatment in MS (Table 2). For example, in EAE, treatment with a selective TNFR2 agonist reduced motor symptom and pain severity and improved various other hallmarks of the disease (155). Cannabinoids are another potential treatment for MS pain, as they are linked to a preferential reduction sTNFα production by both peripheral and central immune cells (156–158), and have shown promising analgesia in clinical trials (159, 160).

Further investigation into similar receptor and/or isoform targeted drugs may make TNF therapy a viable option in MS pain treatment.

GAPS IN KNOWLEDGE AND FUTURE DIRECTIONS

TNFα mediates the development of neuropathic pain in many conditions. While indiscriminate TNF inhibition is effective in some human pain conditions and animal models, it is ineffective and can have deleterious consequences in MS. To develop therapies that effectively target TNF signaling to treat pain in MS we must first focus on developing a better understanding of the cell types, receptors, and downstream pathways involved both peripherally and centrally. Research in the EAE model has already led to the development of promising TNFR1 antagonists and TNFR2 agonists. Other components of the TNF pathway such MAPKs and NFκB may also provide points of intervention. These targeted therapies are the future of pain management in MS and other neuropathic pain conditions.

AUTHOR CONTRIBUTIONS

AM, BK, and JB conceptualized the review. AM wrote the manuscript. BK and JB edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by a Project Grant from the Canadian Institutes of Health Research (FRN-162434) and a Discovery Grant from the MS Society of Canada (EGID-3761).

REFERENCES

1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. (2018) 378:169–80. doi: 10.1056/NEJMra1401483
2. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nat Rev Dis Primers. (2018) 4:43. doi: 10.1038/s41572-018-0041-4
3. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. (2015) 14:406–19. doi: 10.1016/S1474-4422(14)70305-9
4. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. (2017) 13:25–36. doi: 10.1038/nrneurol.2016.187
5. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. (2014) 83:278–86. doi: 10.1212/WNL.0000000000000560

6. Brochet B, Deboire MS, Ouallet JC, Salort E, Bonnet M, Jove J, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: 2-year longitudinal study. Clin J Pain. (2009) 25:211–7. doi: 10.1097/AJP.0b013e3181931437

7. Benson C, Kerr BJ. Pain and cognition in multiple sclerosis. Curr Top Behav Neurosci. (2014) 20:201–15. doi: 10.1007/7854_2014_309

8. O’Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. (2008) 137:96–111. doi: 10.1016/j.pain.2007.08.024

19. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. Theiler’s virus infection: a model for multiple sclerosis. J Neuroimmunol. (2009) 211–7. doi: 10.1016/j.jneumedi.2009.08.006

22. Lu J, Kurejova M, Wirotanseng LN, Linker RA, Kuner R, Tappe-Th eodor. Synaptic alterations and immune response are sexually dimorphic in a non-autoimmune T cell model of multiple sclerosis. J Vis Exp. (2014) 86:51275. doi: 10.3791/51275

26. Anderson AC, Chandraswar R, Lee DH, Sullivan JM, Solomon A, Rodriguez-Manzuet R, et al. A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells. J Immunol. (2012) 188:2084–92. doi: 10.4049/jimmunol.1101288

27. Mendel I, Kerlero de Rosbo N and Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol. (1995) 25:1951–9. doi: 10.1002/eji.1830250723

28. Giralt M, Molinero A, Hidalgo J. Active Induction of Experimental Autoimmune Encephalomyelitis (EAE) with MOG35-55 in the Mouse. Meth Mol Biol. (2018) 1791:227–32. doi: 10.1007/978-1-4939-7862-5_17

29. Segal JP, Banermer CA, Silva JR, Haird CM, Baharooni M, Gilron I, et al. Chronic mechanical hypersensitivity in experimental autoimmune encephalomyelitis is regulated by disease severity and neuroinflammation. Brain Behav Immun. (2020) 89:314–25. doi: 10.1016/j.bbi.2020.07.010

30. Olechowski CJ, Truong HI, Kerr BJ. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain. (2009) 141:156–64. doi: 10.1016/j.pain.2008.11.002

31. Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of interventional therapies. J Neurosci Methods. (2007) 163:245–54. doi: 10.1016/j.jneumeth.2007.03.013

32. Flebbe LM, Braley-Mullen H. Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations. Cell Immunol. (1986) 99:128–39. doi: 10.1016/0008-8749(86)90222-4

33. Khan N, Woodruff TM, Smith MT. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacol Biochem Behav. (2014) 126:13–27. doi: 10.1016/j.pbb.2014.09.003

34. Murphy KL, Fischer R, Swanson KA, Bhatt IJ, Oakley L, Smeye R, et al. Synthetic alterations and immune response are sexually dimorphic in a non-pertussis toxin model of experimental autoimmune encephalomyelitis. Exp Neurol. (2020) 323:113061. doi: 10.1016/j.expneurol.2019.113061

35. Tsukahara R, Yamamoto S, Yoshikawa K, Gotoh M, Tsukahara T, Neyama H, et al. LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model. J Pharmacol Sci. (2018) 136:93–6. doi: 10.15586/codon.multiplesclerosis.2017.ch4

36. Inoue M, Xie W, Matsushita Y, Chen J, Aoki J, Ueda H. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neurosci. (2008) 152:296–8. doi: 10.1016/j.neuroscience.2007.12.041

37. Wang HY, Tsai YJ, Chen SH, Lin CT, Lue JH. Lysophosphatidylcholine causes neuropathic pain via the increase of neuronal nitric oxide synthase in the dorsal root ganglion and cuneate nucleus. Pharmacol Biochem Behav. (2013) 106:47–56. doi: 10.1016/j.pbb.2013.03.002

38. Urañebíeg B, Ito N, Kurano M, Saigusa D, Saito R, Uruno A, et al. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: a study using a rat cauda equina compression model. Sci Rep. (2019) 9:16578. doi: 10.1038/s41598-019-52999-5

39. Schreiner B, Hepper FL, Becher B. Modeling multiple sclerosis in laboratory animals. Semin Immunopathol. (2009) 31:479–95. doi: 10.1007/s00281-009-9179-x

40. Bittner S, Afsari AM, Wiendl H, Meuth SG. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J Vis Exp. (2014) 86:51275. doi: 10.3791/51275

41. Berard JL, Wolak K, Fournier S, David S. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia. (2010) 58:434–45. doi: 10.1002/glia.20935

42. Torkildsen O, Brunborg LA, Myhr KM, Bo L. The cuprizone model: Dos and Do Nots. J Neurol. (2009) 256:231–8. doi: 10.1007/s00415-017-8641-6

43. Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis in mice: a comparative study between different mouse models. J Neuroimmunol. (2012) 239:216–20. doi: 10.1016/j.jneuroim.2011.09.027

44. Maguire et al. TNFa in Pain in MS

Frontiers in Neurology | www.frontiersin.org

8 December 2021 | Volume 12 | Article 780876
demethylated central nervous system. *Neural Regen. Res.* (2022) 17:1042–50. doi: 10.4103/1673-5374.324848

45. Pleemel JR, Michaels NJ, Weisheipt N, Caprariello AV, Keough MB, Rogers JA, et al. Mechanisms of lysophosphatidylcholine-induced demethylation: a primary lipid disrupting myelinospathy. *Glia.* (2018) 66:227–46. doi: 10.1002/glia.23245

46. Tian DH, Perera CJ and Moalem-Taylor G. Neuropathic pain in animal models of nervous system autoimmune diseases. *Mediators Inflamm.* (2013) 2013:298326. doi: 10.1155/2013/298326

47. Thorburn KC, Paylor JW, Webber CA, Winship JR, Kerr BJ. Facial hypersensitivity and trigeminal pathology in mice with experimental autoimmune encephalomyelitis. *Pain.* (2016) 157:627–42. doi: 10.1097/j.pain.0000000000000409

48. Rahn EJ, Iannitti T, Donahue RR, Taylor BK. Sex differences in a mouse model of multiple sclerosis/neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus. *Biol Sex Differ.* (2014) 5:4. doi: 10.1186/2042-6410-5-4

49. Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain:-pharmacological management and pathophysiological insights from rodent EAE models. *Inflammopharmacology.* (2022) 22:1–22. doi: 10.1007/s10877-013-0195-3

50. Aicher SA, Silverman MB, Winkler CW, Bebo BJ. Hyperalgesia in an animal model of multiple sclerosis. *Pain.* (2004) 110:560–70. doi: 10.1016/j.pain.2004.03.025

51. Leung L, Cahill CM. TNF-alpha and neuropathic pain—a review. *J Neuroinflammation.* (2010) 7:27. doi: 10.1186/1742-2094-7-27

52. Ribeiro CM, Oliveira SR, Alfieri DF, Flauzino T, Kaimen-Maciel DR, Simao ANC, et al. Tumor necrosis factor alpha (TNF-alpha) and its soluble receptors are associated with disability, disability progression and with anti-TNF agents. *Transmembrane TNF-alpha:structure, function and interaction with anti-TNF agents. Rheumatology.* (2010) 49:1215–28. doi: 10.1093/rheumatology/keq031

53. Madsen PM, Desu HL, de Rivero Vaccari JP, Florimon Y, Ellman DG, Keane RW, et al. Oligodendrocytes modulate the immune-inflammatory response in EAE via TNFR2 signaling. *Brain Behav Immun.* (2020) 84:132–46. doi: 10.1016/j.bbi.2019.11.017

54. Eridri HT, Naismith JH. TNF alpha and the TNF receptor superfamilies:structure:function-relationship(s). *Microsc Res Tech.* (2000) 50:184–95. doi: 10.1002/1097-0020(20000801)50:3<184::AID-JMET2-3.0.CO;2-H

55. Horisuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha:structure, function and interaction with anti-TNF agents. *Rheumatology.* (2010) 49:1215–28. doi: 10.1093/rheumatology/keq031

56. Yu Y, Cao Y, Bell B, Chen X, Weiss RM, Felder RB, et al. Brain caveolae in an animal model of multiple sclerosis. *Neuroinflammation.* doi: 10.1186/1742-2094-7-27

57. Rauert H, Wicovsky A, Muller N, Siegmund D, Spindler V, Waschke J, et al. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). *J Biol Chem.* (2010) 285:7394–404. doi: 10.1074/jbc.M109.037341

63. Tsao DH, McDonagh T, Tellier JB, Hsu S, Malakian K, Xu GY, et al. Solution structure of N-TRADD and characterization of the interaction of N-TRADD and C-TRAF2, a key step in the TNFR1 signaling pathway. *Mol Cell.* (2000) 5:1051–7. doi: 10.1016/S1097-2765(00)80275-1

64. Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L, et al. RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review). *Int J Mol Med.* (2019) 44:771–86. doi: 10.3892/ijmm.2019.4244

65. Borghi A, Verstrepen L, Beyaert R. TRAF2 multitasking in TNF receptor-coupled adaptive immune responses. *Cell Signal.* (2018) 104:579–88. doi: 10.1016/j.cellsig.2018.01.039

66. Jupp OJ, McFarlane SM, Anderson HM, Littlejohn AF, Mohamed AA, MacKay RH, MacEwan DJ, et al. Type II tumour necrosis factor alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. *Biochem J.* (2001) 359:525–35. doi: 10.1042/bj3590525

67. Yang S, Wang J, Brand DD, Zheng SG. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications. *Front Immunol.* (2018) 9:784. doi: 10.3389/fimmu.2018.00784

68. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, Min W, Eriksson BM transtactives vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. *J Biol Chem.* (2003) 278:51267–76. doi: 10.1074/jbc.M307678200

69. Wei KH, Na XD, Liao GJ, Chen QY, Cui Y, Chen FY, Li YY, Liu XG, et al. The up-regulation of IL-6 in DRG and spinal dorsal horn contributes to neuropathic pain following L5 ventral root transection. *Exp Neurol.* (2013) 241:159–68. doi: 10.1016/j.expneurol.2012.12.007

70. Wu Y, Na X, Zang Y, Cui Y, Xin W, Pang R, Liu X, et al. Upregulation of tumor necrosis factor-alpha in nucleus accumbens attenuates morphine-induced rewarding in a neuropathic pain model. *Biochem Biophys Res Commun.* (2014) 449:502–7. doi: 10.1016/j.bbrc.2014.05.025

71. Geneyva S, Finckh A, Payer M, Mezin F, Tessitore E, Gabay C, et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. *Spine.* (2008) 33:2041–6. doi: 10.1097/BRS.0b013e318138b386

72. Sorkin LS, Doorn CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. *J Peripher Nerv Syst.* (2000) 5:96–100. doi: 10.1046/j.1529-8027.2000.00012.x

73. Wagner R, Myers RR. Endoneurial application of TNF-alpha produces neuropathic pain behaviors. *Neuroreport.* (1996) 7:2897–901. doi: 10.1097/00001756-199611250-00018

74. Schafers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. *Pain.* (2003) 104:579–88. doi: 10.1016/S0304-3959(03)00115-5

75. Schafers M, Lee DH, Bros D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. *J Neurosci.* (2003) 23:3028–38. doi: 10.1523/JNEUROSCI.23-07-03028.2003

76. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. *Exp Neurol.* (1998) 151:138–42. doi: 10.1006/exnr.1998.6797

77. Shubayev VI, Myers RR. Uregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve
The role of TNF-α

Zhao H, Alam A, Chen Q, AE, Pal A, Eguchi S, Wu L, and Ma D. The role of TNF-α in peripheral neuropathy. J Neuroinflammation. (2011) 8:1. doi: 10.1186/1742-2094-8-1

Ferguson AR, Christensen RN, Gensel JC, Miller BA, Sun F, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK. J Neurosci. (2005) 25:11329–37. doi: 10.1523/JNEUROSCI.2873-05.2005

Taylor CA, Zheng Q, Liu Z, Thompson JE. Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells. Mol Cancer. (2013) 12:202. doi: 10.1186/1476-4598-12-202

Yousuf MS, NOh MC, Friedman TN, Zubkow K, Johnson JC, Tenorio G, et al. Sensory nerves of the dorsal root ganglia become hyperexcitable in a T-cell-mediated MOG-EAE model of multiple sclerosis. eNeuro. (2019) 6:ENEURO.0024-19.2019. doi: 10.1523/ENEURO.0024-19.2019

Wajant H, Siegmund D. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. Front Cell Dev Biol. (2015) 3:91. doi: 10.3389/fcell.2019.00091

Parmeswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Exp. (2010) 20:87–103. doi: 10.1615/CritRevEukaryotGeneExp.v20.i2.10

Wheeler MA, Heffner DL, Kim S, Espy SM, Spano AJ, Cleland CL, et al. TNF-alpha/TNFalpha signaling is required for the development and function of primary nociceptors. Neuron. (2014) 82:587–602. doi: 10.1016/j.neuron.2014.04.009

Gangadhuran V, Kuner R. Pain hypersensitivity mechanisms at a glance. Dis Model Mech. (2013) 6:889–95. doi: 10.1242/dmm.011502

Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. (2001) 413:203–10. doi: 10.1038/35093019

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. (2009) 10:895–926. doi: 10.1016/j.jpain.2009.06.012

Ten Klooster PM, de Graaf N, Vonkeman HE. Association between pain phenotype and disease activity in rheumatoid arthritis patients: non-interventional, longitudinal cohort study. Arthritis Res Ther. (2019) 21:257. doi: 10.1186/s13075-019-2042-4

Sunderkotter C, Toshniwal G, Dureja GP. Ketamine as an adjuvant in sympathetic blocks for management of central sensitization following peripheral nerve injury. J Brachial Plex Peripher Nerve Inj. (2008) 3:22. doi: 10.1186/1749-7221-3-22
158. Zheng ZM, Specter SC. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. *Int J Immunopharmacol*. (1996) 18:53–68. doi: 10.1016/0192-0561(95)00107-7

159. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. *CNS Drugs*. (2011) 25:187–201. doi: 10.2165/11539000-000000000-00000

160. Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. *Curr Neurol Neurosci Rep*. (2018) 18:8. doi: 10.1007/s11910-018-0814-x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Maguire, Bethea and Kerr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.